Cantargia AB (Lund, Sweden) is developing an antibody against the IL1RAP target molecule for cancer treatment. Preclinical data indicate that the antibody has the potential to be used for treatment of several forms of cancer. Cantargia will be focusing the initial development activities on non-small cell lung cancer (NSCLC) and pancreatic cancer. A product candidate CAN04 has been selected and a clinical phase I/IIa study in these cancers was initiated in Q3 2017 with phase I results expected during summer 2018. The goal is to develop a new treatment for future cancer therapies.
CAN04 has been designed to block the interleukin-1 signaling pathway which the cancer cells utilize to mediate inflammation in order to promote tumor growth. In addition, CAN04 has been designed to stimulate the immune system to eliminate the cancer cells.
The company is listed on NASDAQ Stockholm.